Linear univariate and multivariate modeling of locoregional control (LRC) and overall survival (OS) probabilities as a function of clinical and biomarker covariates for the entire testing cohort
| Endpoint . | Biomarker . | Spearman's rho coefficient . | Univariate P value . | Multivariate P value . |
|---|---|---|---|---|
| LRC | Ku80 | 0.487 | <0.005 | 0.007 |
| DNA-PKcs | 0.305 | 0.006 | NS | |
| p16 | −0.224 | 0.04 | NS | |
| OS | Ku80 | 0.465 | <0.005 | <0.005 |
| T Stage | 0.316 | <0.005 | NS | |
| HPV | −0.294 | 0.008 | NS | |
| p16 | −0.284 | 0.01 | 0.02 | |
| DNA-PKcs | 0.27 | 0.02 | NS | |
| Shh | 0.267 | 0.02 | NS | |
| Rb | 0.263 | 0.02 | NS | |
| BRCA1 | 0.252 | 0.03 | NS |
| Endpoint . | Biomarker . | Spearman's rho coefficient . | Univariate P value . | Multivariate P value . |
|---|---|---|---|---|
| LRC | Ku80 | 0.487 | <0.005 | 0.007 |
| DNA-PKcs | 0.305 | 0.006 | NS | |
| p16 | −0.224 | 0.04 | NS | |
| OS | Ku80 | 0.465 | <0.005 | <0.005 |
| T Stage | 0.316 | <0.005 | NS | |
| HPV | −0.294 | 0.008 | NS | |
| p16 | −0.284 | 0.01 | 0.02 | |
| DNA-PKcs | 0.27 | 0.02 | NS | |
| Shh | 0.267 | 0.02 | NS | |
| Rb | 0.263 | 0.02 | NS | |
| BRCA1 | 0.252 | 0.03 | NS |
NOTE. Positive correlations imply a larger risk of failure for increasing expression values or stage. NS, not significant (P > 0.05). All variables listed were included in both the univariate and multivariate analyses. Other variables included in the univariate analysis that were not predictive of outcomes are not listed here; these included N stage, overall stage, radiation dose, history of tobacco use, use of chemotherapy, primary tumor location, and the remainder of the biomarkers listed in Supplementary Table S1.